Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for steroid-refractory chronic graft-versus-host disease
NL-OMON27646Not yet recruiting
- Sponsor
- Roche
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in chronic graft-versus-host disease (cGVHD), sponsored by Roche. Primary endpoint: Proportion of complete and partial responses. Planned start Jul 2006; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NL-OMON27646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27646.